EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

Liver Cancer

ISSN 1664-5553 · S. Karger AG

Neueste Artikel

  1. Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

    Stephen Lam Chan, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Jee Hyun Kim, Binh Pham, Jung Yong Hong, Dirk-Thomas Waldschmidt, Donatella Marino, Jie Xin Joycelyn Lee, René Gerolami, Adam M. Burgoyne, Qiao Li, Hitomi Nakamura, Peng Sun, Boris Baur, Lorenza Rimassa

    Erschienen: 2025-12-18DOI: 10.1159/000549955

  2. Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study

    Ko Hashimoto, Tomokazu Kawaoka, Tomoaki Emori, Aiko Tanaka, Yuki Shirane, Ryoichi Miura, Yasutoshi Fujii, Hikaru Nakahara, Kenji Yamaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, C. Nelson Hayes, Akira Hiramatsu, Kei Amioka, Michihiro Nonaka, Yasuyuki Aisaka, Kei Morio, Takashi Moriya, Yuji Teraoka, Hirotaka Kono, Yosuke Suehiro, Keiichi Masaki, Kazuki Ohya, Shintaro Takaki, Nami Mori, Keiji Tsuji, Yumi Kosaka, Takashi Nakahara, Hiroshi Aikata, Masataka Tsuge, Shiro Oka

    Erschienen: 2025-12-09DOI: 10.1159/000549979

  3. Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy

    Camilla De Carlo, Reha Akpinar, Barbara Durante, Tiziana Pressiani, Julien Calderaro, Salvatore Lorenzo Renne, Angelo Pirozzi, Elena Valenzi, Irene Oi-lin Ng, Tan To Cheung, Albino Eccher, Pamela Sighinolfi, Erica Villa, Massimo Iavarone, Marco Maggioni, Yu-Yun Shao, Sara Lonardi, Mario Domenico Rizzato, Antonio De Rosa, Matteo Fassan, Valentina Angerilli, Federica Pedica, Margherita Rimini, Andrea Casadei Gardini, Armando Santoro, Young Nyun Park, Massimo Roncalli, Luigi Terracciano, Salvatore Piscuoglio, Lorenza Rimassa, Luca Di Tommaso

    Erschienen: 2025-09-19DOI: 10.1159/000547669

  4. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)

    Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Mengsu Zeng, Weiping Zhou, Lianxin Liu, Tianfu Wen, Ming Kuang, Bixiang Zhang, Kaishan Tao, Guohong Han, Zhiping Yan, Maoqiang Wang, Ruibao Liu, Jinhe Guo, Zhaochong Zeng, Ping Liang, Zhenggang Ren, Jinlin Hou, Yanqiao Zhang, Xiufeng Liu, Hongming Pan, Feng Bi, Changhong Liang, Min Chen, Fuhua Yan, Huixiong Xu, Xiaoyan Xie, Shenghong Ju, Yuan Ji, Jingping Yun, Zengshan Li, Xueli Bai, Dingfang Cai, Weixia Chen, Yajin Chen, Yongjun Chen, Wenwu Cheng, Shuqun Cheng

    Erschienen: 2025-07-10DOI: 10.1159/000546574

  5. Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study

    Masatoshi Kudo, Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita, Shigeo Shimose, Kazushi Numata, Yuzo Kodama, Shinji Itoh, Yasuhito Tanaka, Hidekatsu Kuroda, Hiroshi Aikata, Atsushi Hiraoka, Michihisa Moriguchi, Ryosuke Tateishi, Sadahisa Ogasawara, Kouji Yamamoto, Masafumi Ikeda

    Erschienen: 2025-06-19DOI: 10.1159/000546899

  6. Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

    Yoon Jun Kim, Philippe Merle, Richard S. Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Ho Yeong Lim, Masafumi Ikeda, Alessandro Granito, Gianluca Masi, René Gerolami, Sung Bum Cho, Chih-Hung Hsu, Yi-Hsiang Huang, Long-Bin Jeng, Do Young Kim, Shi-Ming Lin, Matthias Pinter, Guoliang Shao, Naoya Kato, Masayuki Kurosaki, Kazushi Numata, Kung-Kai Kuo, Yilei Mao, Yih-Jyh Lin, Kangshun Zhu, Philip Twumasi-Ankrah, Javeed Khan, Maria Awan, Kirhan Ozgurdal, Shukui Qin

    Erschienen: 2024-12-18DOI: 10.1159/000542285

  7. Probability of Lymph Node Metastases in Patients Undergoing Adequate Lymphadenectomy during Surgery for Intrahepatic Cholangiocarcinoma: A Retrospective Multicenter Study

    Carlo Sposito, Alessandro Cucchetti, Francesca Ratti, Laura Alaimo, Francesco Ardito, Stefano Di Sandro, Matteo Serenari, Giammauro Berardi, Marianna Maspero, Giuseppe Maria Ettorre, Matteo Cescon, Fabrizio Di Benedetto, Felice Giuliante, Andrea Ruzzenente, Giorgio Ercolani, Luca Aldrighetti, Vincenzo Mazzaferro

    Erschienen: 2024-10-16DOI: 10.1159/000541646

  8. Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023

    Keiichi Akahoshi, Junichi Shindoh, Minoru Tanabe, Shunichi Ariizumi, Susumu Eguchi, Yukiyasu Okamura, Masaki Kaibori, Shoji Kubo, Mitsuo Shimada, Akinobu Taketomi, Nobuyuki Takemura, Hiroaki Nagano, Masafumi Nakamura, Kiyoshi Hasegawa, Etsuro Hatano, Tomoharu Yoshizumi, Itaru Endo, Norihiro Kokudo

    Erschienen: 2024-03-29DOI: 10.1159/000538627

Jahrgänge

2026 · 562025 · 842024 · 892023 · 652022 · 682021 · 682020 · 822019 · 642018 · 472017 · 552016 · 332015 · 312014 · 242013 · 252012 · 26

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.